Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$11.18 - $15.46 $185,465 - $256,465
-16,589 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $235,729 - $292,795
16,589 New
16,589 $238,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.43B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Polar Asset Management Partners Inc. Portfolio

Follow Polar Asset Management Partners Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polar Asset Management Partners Inc., based on Form 13F filings with the SEC.

News

Stay updated on Polar Asset Management Partners Inc. with notifications on news.